Oncothyreon Announces Appointment of Ted W. Love, M.D. to Board of Directors
SEATTLE, Sept. 6, 2013
SEATTLE, Sept. 6, 2013 /PRNewswire/ - Oncothyreon Inc. (NASDAQ: ONTY) today
announced the appointment of Ted W. Love, M.D., to its board of directors.
"We are pleased to welcome Dr. Love, with his extensive experience in drug
development, operations and corporate governance, to our board of directors,"
said Robert L. Kirkman, M.D., President and Chief Executive Officer of
Dr. Love served as Executive Vice President and Head of Research and
Development and Technical Operations at Onyx Pharmaceuticals, Inc., from
February 2010 to August 2012. From 2001 to January 2009, Dr. Love served as
Chairman and Chief Executive Officer of Nuvelo, Inc. Dr. Love joined Nuvelo
from Theravance, Inc., where he served as Senior Vice President of Development
from 1998 to 2001. Previously, he spent six years at Genentech, Inc., where he
held a number of senior management positions in medical affairs and product
development and served as chairman of Genentech's Product Development
Committee. Dr. Love also serves as a member of the boards of directors of
biopharmaceutical companies Santarus, Inc., Amicus, Inc., and Kalobios, Inc.
Until April 2012, he served on the California Independent Citizens' Oversight
Committee. Dr. Love earned his Bachelor of Science in molecular biology from
Haverford College and his M.D. from Yale Medical School.
Oncothyreon is a biotechnology company specializing in the development of
innovative therapeutic products for the treatment of cancer. Oncothyreon's
goal is to develop and commercialize novel synthetic vaccines and targeted
small molecules that have the potential to improve the lives and outcomes of
cancer patients. For more information, visit www.oncothyreon.com.
Additional information relating to Oncothyreon can be found on EDGAR at
www.sec.gov and on SEDAR at www.sedar.com.
SOURCE Oncothyreon Inc.
Investor and Media Relations Contact:
Press spacebar to pause and continue. Press esc to stop.